Intestinal Homeostasis and its Breakdown
Fiona Powrie, GBR

pic-PowrieFiona Powrie is the Director of the Kennedy Institute of Rheumatology and Principal Investigator in the Translational Gastroenterology Unit, University of Oxford. Her research interests include characterisation of the interaction between the intestinal microbiota and the host immune system and how this mutualistic relationship breaks down in inflammatory bowel disease. Her work has identified the functional role of regulatory T cells in intestinal homeostasis and shed light on their development and mechanism of action. She has also shown that both adaptive and innate immune mechanisms contribute to intestinal inflammation and identified the IL-23 pathway as a pivotal player in the pathogenesis of chronic intestinal inflammation. Her current work seeks to translate findings from model systems into the clinic in inflammatory bowel disease patients. Fiona Powrie received the Ita Askonas Award from the European Federation of Immunological Societies for her contribution to immunology in Europe and the Louis Jeantet Prize for Medicine 2012. She was elected a Fellow of the Royal Society in 2011, EMBO in 2013 and the Academy of Medical Sciences in 2014.


Cancer Therapy
Michael C. Milone, USA

Milone-MichaelDr. Milone received his M.D. and Ph.D. in experimental pathology in 1999 from Rutgers-New Jersey Medical School (formerly the University of Medicine and Dentistry of New Jersey). After an Internship in Internal Medicine at the Hospital of the University of Pennsylvania, he completed post-graduate medical training in Clinical Pathology, Transfusion Medicine and Laboratory Toxicology. Following clinical training, Dr. Milone pursued post-doctoral research training in cancer immunology and adoptive immunotherapy with Dr. Carl June at the University of Pennsylvania where he performed basic research to develop CTL019, a genetically modified T cell therapy for B-cell leukemia and lymphoma that has been licensed by Novartis and undergoing early phase clinical testing. He is currently an Assistant Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. At present, Dr. Milone’s laboratory is focused on T cell biology and the development of new techniques for culturing and genetically modifying T lymphocytes for adoptive immunotherapy of cancer.


Luke O`Neill, IRL

pic-ONeillProfessor Luke O’Neill was appointed to the Chair of Biochemistry at Trinity College Dublin in 2008, where he leads the Inflammation Research Group.  He has a PhD in Pharmacology from the University of London and carried out Post-Doctoral research at Cambridge U.K. on the pro-inflammatory cytokine IL-1 and innate immune signaling. His research is in the area of the molecular basis to inflammatory diseases. He has won numerous awards for his research, notably the Royal Irish Academy Medal for Biochemistry, The Irish Society for Immunology medal, the Royal Dublin Society/ Irish Times Boyle medal for Scientific Excellence, the Science Foundation Ireland Researcher of the Year Award and in 2014 the European Federation of Immunology Societies Medal. He was elected a member of EMBO in 2005.  In 2014 he was named by Thompson Reuters as one of the world’s most influential scientists, being in the top 1% in both Immunology and Pharmacology/Toxicology.  He is a co-founder and director of Opsona Therapeutics, a drug development company working in the area of Toll-like receptors.


The B cell receptor in B cell development, memory and malignancies
Klaus Rajewsky, GER

pic-RajewskyKlaus Rajewsky and collaborators developed a general method of targeted mutagenesis in mouse embryonic stem cells by introducing bacteriophage- and yeast-derived recombination systems, which opened the way for conditional gene targeting. Using this and other methods in their immunological work, they developed, together with N. A. Mitchison and N. K. Jerne, the antigen-bridge model of T-B cell cooperation, identified germinal centers as the sites of antibody somatic hypermutation, the B cell antigen receptor as a survival determinant of B cells, and the germinal center as a major site of human B cell lymphomagenesis, including Hodgkin lymphoma. Over the last years the work of his group has focused on mechanisms of microRNA control and the development of mouse models of human B cell lymphomas.
Klaus Rajewsky obtained his degree in medicine (MD) at the University of Frankfurt in 1962. After postdoctoral work at the Institut Pasteur in Paris he built an immunology department at the Institute for Genetics at the University of Cologne where he stayed for 38 years, was the founding Program Coordinator of the EMBL Mouse Biology Program at Monterotondo near Rome, worked for 10 years at Harvard Medical School in Boston, and is since 2012 at the Max-Delbrück-Center for Molecular Medicine in Berlin.
Klaus Rajewsky won numerous scientific awards and is a member of several learned societies including the National Academy of Sciences of the USA and the American Academy of Arts and Sciences.